{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:50:46Z","timestamp":1791175846105,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,16]],"date-time":"2012-12-16T00:00:00Z","timestamp":1355616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,12,16]],"date-time":"2012-12-16T00:00:00Z","timestamp":1355616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s11894-012-0303-3","type":"journal-article","created":{"date-parts":[[2012,12,18]],"date-time":"2012-12-18T12:16:08Z","timestamp":1355832968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["What Are the Promising New Therapies in the Field of Chronic Hepatitis C After the First-Generation Direct-Acting Antivirals?"],"prefix":"10.1007","volume":"15","author":[{"given":"Douglas","family":"Hunt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Pockros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,16]]},"reference":[{"key":"303_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrmicro1645","volume":"5","author":"D Moradpour","year":"2007","unstructured":"Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007;5:453\u201363.","journal-title":"Nat Rev Microbiol"},{"key":"303_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/13305","volume":"6","author":"CA Lesburg","year":"1999","unstructured":"Lesburg CA, Cable MB, Ferrari E, et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol. 1999;6:937\u201343.","journal-title":"Nat Struct Biol"},{"key":"303_CR3","unstructured":"Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H. Short Guide to Hepatitis C 2012 Edition; Flying Publisher & Kamps."},{"key":"303_CR4","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.2174\/156802607781212211","volume":"7","author":"U Koch","year":"2007","unstructured":"Koch U, Narjes F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr Top Med Chem. 2007;7:1302\u201329.","journal-title":"Curr Top Med Chem"},{"key":"303_CR5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S0168-8278(11)61361-5","volume":"54","author":"P Pockros","year":"2011","unstructured":"Pockros P, Jensen DM, Tsai N. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon\/ribavirin in treatment-naive HCV G1\/4 patients: interim analysis of the JUMP-C trial. J Hepatol. 2011;54:538.","journal-title":"J Hepatol"},{"issue":"Supplement 2","key":"303_CR6","doi-asserted-by":"publisher","first-page":"S477","DOI":"10.1016\/S0168-8278(12)61217-3","volume":"56","author":"P Pockros","year":"2012","unstructured":"Pockros P, Jensen D, Tsai N, et al. SVR-12 among G1\/4 Treatment-Na\u00efve Patients receiving Mericitabine in Combination with PEG-IFN\u03b1-2A\/RBV: Interim Analysis from the Jump-C Study. J Hepatol. 2012;56(Supplement 2):S477.","journal-title":"J Hepatol"},{"key":"303_CR7","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","volume":"376","author":"EJ Gane","year":"2010","unstructured":"Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376:1467\u201375.","journal-title":"Lancet"},{"issue":"Supplement 2","key":"303_CR8","doi-asserted-by":"publisher","first-page":"S555","DOI":"10.1016\/S0168-8278(12)61423-8","volume":"56","author":"EJ Gane","year":"2012","unstructured":"Gane EJ, Pockros P, Zeuzem S, et al. Interferon-Free Treatment with a combination of Mericitabine and Danoprevir\/R with or without Ribavirin in Treatment-Na\u00efve HCV Genotype 1-Infected Patients. J Hepatol. 2012;56(Supplement 2):S555.","journal-title":"J Hepatol"},{"key":"303_CR9","unstructured":"Hoffmann-La Roche. ANNAPURNA: A study of the combination of RO5466731, RO5190591, ritonavir and Copegus(ribavirin) with or without RO5024048 in patients with chronic hepatitis C who are either treatment-naive or have previously experienced a null response to interferon-based treatment [ClinicalTrials.gov identifier NCT01628094]. US National Institutes of Health, ClinicalTrials.gov [online] Available from URL:http:\/\/www.clinicaltrials.gov [Accessed 2012 Aug26]"},{"issue":"suppl 1","key":"303_CR10","doi-asserted-by":"publisher","first-page":"S544","DOI":"10.1016\/S0168-8278(11)61374-3","volume":"54","author":"DR Nelson","year":"2011","unstructured":"Nelson DR, Lalezari J, Lawitz E, et al. Once daily PSI-7977 plus PEG-IFN\/ RBV in HCV GT1: 98\u00a0% rapd virologic response, complete early virologic response: the PROTON study. J Hepatol. 2011;54 suppl 1:S544. Abstract 1372.","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"303_CR11","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S0168-8278(11)60063-9","volume":"54","author":"J Lalezari","year":"2011","unstructured":"Lalezari J, Lawitz E, Rodriguez-Torres M, et al. Once daily PSI-7977 plus PEGIFN\/RBV in a phase 2B trial: rapid virologic suppression in treatment-na\u00efve patients with HCV GT2\/GT3. J Hepatol. 2011;54 suppl 1:S28. Abstract 61.","journal-title":"J Hepatol"},{"key":"303_CR12","first-page":"113","volume":"54","author":"E Lawitz","year":"2011","unstructured":"Lawitz E, Lalezari JP, Hassanein T, et al. Once-daily PSI-7977 plus peg\/RBV in treatment-naive pateints with HCV GT1: robust end of treatment response rates are sustained post-treatment. Hepatology. 2011;54:113.","journal-title":"Hepatology"},{"key":"303_CR13","unstructured":"Gane EJ, Stedman CA, Hyland RH, et al. PSI-7977: ELECTRON Interferon is not required for Sustained Virologic Response in Treatment-Na\u00efve Patients with HCV GT2 or GT3 . 62nd Annual Meeting of the American Association for the Study of Liver Diseases November 4\u20138, 2011 San Francisco, CA."},{"key":"303_CR14","unstructured":"Gane EJ, Stedman C, Anderson J, et al. 100\u00a0% Rapid Virologic Response for PSI-7977 + Ribavirin in Genotype 1 Null Responders (ELECTRON): Early Viral Decline Similar to that Observed in Genotype 1 and Genotype 2\/3 Treatment-na\u00efve Patients. 19th Conference on Retroviruses and Opportunistic Infections, March 5\u20138, 2012; abstract 54LB."},{"key":"303_CR15","unstructured":"Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Na\u00efve Hepatitis C Patients- Interim Results Reported from ELECTRON and QUANTUM Studies. Barcelona, Spain, Apr 19, 2012.Gilead Sciences, Inc."},{"key":"303_CR16","doi-asserted-by":"crossref","unstructured":"Sulkowski M, Gardiner D, Lawitz E, et al. Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +\/-ribavirin, in treatment-na\u00efve patients with chronic HCV GT1, 2, or 3. 47th Annual Meeting of the European Association for the Study of the Liver, April 18\u201322, 2012, Barcelona, Spain; LB abstract 1422.","DOI":"10.1016\/S0168-8278(12)61433-0"},{"key":"303_CR17","unstructured":"http:\/\/www.clinicaltrials.gov: Hepatitis C and Gilead Sciences. August 19, 2012."},{"key":"303_CR18","unstructured":"Bristol-Myers to Suspend a Drug Study. The New York Times, August 3, 2012."},{"key":"303_CR19","doi-asserted-by":"crossref","unstructured":"Lawitz E, Poordad F, Kowdley KV, et al. A 12-week interferon- free regimen of ABT-450\/r, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response. 2012 Apr 18\u201322; Barcelona.","DOI":"10.1016\/S0168-8278(12)60027-0"},{"key":"303_CR20","doi-asserted-by":"crossref","unstructured":"Poordad F, Lawitz E, Kowdley KV, et al. 12-Week interferon- free regimen of ABT-450\/r+ABT-333+ribavirin achieved SVR12 in more than 90\u00a0% of treatment-na\u00efve HCV non-responders [abstract no. 1399]. 47th Annual Meeting of the European Association for the Study of the Liver;2012 Apr 18\u201322; Barcelona.","DOI":"10.1016\/S0168-8278(12)61410-X"},{"issue":"6","key":"303_CR21","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1053\/j.gastro.2011.08.051","volume":"141","author":"S Zeuzem","year":"2011","unstructured":"Zeuzem S, Asselah T, Angus P, et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology. 2011;141(6):2047\u201355.","journal-title":"Gastroenterology"},{"key":"303_CR22","unstructured":"Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PEGIFN\/RBV for up to 28\u00a0days in treatment-na\u0131ve, genotype 1 HCV subjects [abstract no. LB1]. 61st Annual Meeting of the American Association for the Study of Liver Diseases; 2010 Oct 29\u2013Nov 2; Boston (MA)."},{"key":"303_CR23","doi-asserted-by":"crossref","unstructured":"Sulkowski M, Rodriguez-Torres M, Lawitz E, et al. High sustained virologic response rate in treatment-naive HCV genotype 1a and 1b patients treated for 12\u00a0weeks with an interferon-free all-oral quad regimen: interim results [abstract no. 1421]. 47th Annual Meeting of the European Association for the Study of the Liver; 2012 Apr 18\u201322; Barcelona.","DOI":"10.1016\/S0168-8278(12)61432-9"},{"issue":"Suppl 1","key":"303_CR24","doi-asserted-by":"publisher","first-page":"S382","DOI":"10.1016\/S0168-8278(09)61054-0","volume":"50","author":"I Jacobson","year":"2009","unstructured":"Jacobson I, Pockros P, Lalezari J, et al. Antiviral activity of Filibuvir in combination with pegylated interferon alfa-2a and ribavirin for 28\u00a0days in treatment na\u00efve patients chronically infected with HCV genotype 1. J Hepatol. 2009;50 Suppl 1:S382.","journal-title":"J Hepatol"},{"key":"303_CR25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","volume":"138","author":"C Sarrazin","year":"2010","unstructured":"Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138:447\u201362.","journal-title":"Gastroenterology"},{"key":"303_CR26","doi-asserted-by":"publisher","first-page":"4356","DOI":"10.1128\/AAC.00444-08","volume":"52","author":"S Ali","year":"2008","unstructured":"Ali S, Leveque V, Le Pogam S, et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother. 2008;52:4356\u201369.","journal-title":"Antimicrob Agents Chemother"},{"key":"303_CR27","first-page":"S864","volume":"46","author":"C Cooper","year":"2007","unstructured":"Cooper C, Lawitz E, Ghali P, et al. Antiviral activity of the non-nucleoside polymerase inhibitor, VCH-759, in chronic hepatitis C patients: Results from a randomized, double-blind, placebo-controlled, ascending multiple dose study. Hepatol. 2007;46:S864.","journal-title":"Hepatol"},{"key":"303_CR28","unstructured":"Erhardt A, Deterding K, Benhamou Y, et al. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase."},{"key":"303_CR29","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Soriano V, Asselah T, et al. SVR4 and SVR12 with an interferon-free regimen of BI201335 and BI207127, +\/- ribavirin, in treatment-na\u00efve patients with genotype-1 HCV infection: Interim results of SOUND-C2.[ abstract no. 101] 47th Annual Meeting of the European Association for the Study of the Liver, April 18\u201322, 2012, Barcelona, Spain.","DOI":"10.1016\/S0168-8278(12)60115-9"},{"key":"303_CR30","first-page":"1442","volume":"54","author":"DR Nelson","year":"2011","unstructured":"Nelson DR, Gane EJ, Jacobson IM, et al. VX- 222\/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype 1 HCV patients treated for12 weeks: Zenith study, SVR 12 interim analyses [abstract]. Hepatology. 2011;54:1442.","journal-title":"Hepatology"},{"key":"303_CR31","doi-asserted-by":"crossref","unstructured":"Lawitz E, Rodriguez-Torres M, Rustgi VK, et al.Safety and Antiviral Activity of ANA598 in Combination with Pegylated Interferon \u03b12A Plus Ribavirin in Treatment-Na\u00efve Genotype-1 Chronic HCV Patients.[abstract no. LB13] 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010). Vienna, Austria. April 14\u201318, 2010.","DOI":"10.1016\/S0168-8278(10)61200-7"},{"key":"303_CR32","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nature04193","volume":"437","author":"E Meylan","year":"2005","unstructured":"Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature. 2005;437:1167\u201372.","journal-title":"Nature"},{"key":"303_CR33","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3851\/IMP1894","volume":"16","author":"M Manns","year":"2011","unstructured":"Manns M, Reesink H, Berg T, et al. Rapid viral response of once-daily TMC435 plus pegylated interferon\/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther. 2011;16:1021\u201333.","journal-title":"Antivir Ther"},{"key":"303_CR34","first-page":"706","volume":"52","author":"DM Brainard","year":"2010","unstructured":"Brainard DM, Petry A, Van Dyck K, et al. Safety and antiviral activity of MK-5172, a novel HCV NS3\/4A protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology. 2010;52:706.","journal-title":"Hepatology"},{"key":"303_CR35","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1053\/j.gastro.2009.10.033","volume":"138","author":"HW Reesink","year":"2010","unstructured":"Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology. 2010;138:913\u201321.","journal-title":"Gastroenterology"},{"issue":"14","key":"303_CR36","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.2165\/11635560-000000000-00000","volume":"72","author":"PJ Pockros","year":"2012","unstructured":"Pockros PJ. Interferon free hepatitis C therapy: how close are we? Drugs. 2012;72(14):1825\u201331.","journal-title":"Drugs"},{"key":"303_CR37","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1006\/viro.2001.1225","volume":"292","author":"ST Shi","year":"2002","unstructured":"Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, Lai MM. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology. 2002;292:198\u2013210.","journal-title":"Virology"},{"key":"303_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1128\/CMR.00010-06","volume":"20","author":"A Wohnsland","year":"2007","unstructured":"Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev. 2007;20:23\u201338.","journal-title":"Clin Microbiol Rev"},{"key":"303_CR39","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465:96\u2013100.","journal-title":"Nature"},{"key":"303_CR40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jhep.2010.06.027","volume":"54","author":"C Hezode","year":"2011","unstructured":"Hezode C, Hirschfield GM, Ghesquiere W, et al. BMS-790052, a NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-navie HCVgentoype 1 or 4 patients: phase 2b AI444010 study interim week 12 results. Hepatology. 2011;54:115.","journal-title":"Hepatology"},{"issue":"3","key":"303_CR41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1056\/NEJMoa1104430","volume":"366","author":"AS Lok","year":"2012","unstructured":"Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366(3):216\u201324.","journal-title":"N Engl J Med"},{"issue":"4","key":"303_CR42","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jcv.2012.04.024","volume":"54","author":"F Suzuki","year":"2012","unstructured":"Suzuki F, Sezaki H, Akuta N, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol. 2012;54(4):352\u20134.","journal-title":"J Clin Virol"},{"key":"303_CR43","unstructured":"Chayama K, Takahashi S, Kawakami Y, et al. Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90\u00a0% sustained virologic response (SVR12) in HCV genotype 1b-infected null responders [abstract no. LB-4]. 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 2011 Nov 4\u20138; San Francisco (CA)."},{"key":"303_CR44","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/hep.22131","volume":"47","author":"R Flisiak","year":"2008","unstructured":"Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent antihepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology. 2008;47:817\u201326.","journal-title":"Hepatology"},{"key":"303_CR45","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/hep.22835","volume":"49","author":"R Flisiak","year":"2009","unstructured":"Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFN alpha 2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology. 2009;49:1460\u20138.","journal-title":"Hepatology"},{"key":"303_CR46","doi-asserted-by":"crossref","unstructured":"Pawlotsky JM, Sarin SK, Foster G, et al. Alisporivir plus ribavirin is highly effective as interferon-free or interferon add- on regimen in previously untreated HCV-GT2 or GT3 patients: SVR12 results from VITAL-1 phase 2b study[abstract no. LB 11]. 47th Annual Meeting of the European Association for the Study of the Liver; 2012 Apr 18\u201322; Barcelona.","DOI":"10.1016\/S0168-8278(12)61416-0"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-012-0303-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-012-0303-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-012-0303-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-012-0303-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:11:12Z","timestamp":1659089472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-012-0303-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,16]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["303"],"URL":"https:\/\/doi.org\/10.1007\/s11894-012-0303-3","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,16]]},"assertion":[{"value":"16 December 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"303"}}